Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Drug

Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal

Fineline Cube Jan 22, 2026
Company Deals

Eyebright Medical to Acquire Control of Delta Medical in $143 M Sports‑Medicine Deal

Fineline Cube Jan 22, 2026
Company Deals

Insilico Licenses NLRP3 Inhibitor ISM8969 to Hengtai in $64M CNS Drug Deal

Fineline Cube Jan 20, 2026
Company Deals

Shionogi Boosts ViiV Stake to 21.7% in $2.1 Billion Deal, Doubles Down on HIV Focus

Fineline Cube Jan 20, 2026
Company Deals Medical Device

EasyDiagnosis Bio to Acquire 51% of Ailex Medical in $5.1M Deal, Gains IVD Platform

Fineline Cube Jan 20, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Deals Drug

Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal

Fineline Cube Jan 22, 2026
Company Drug

Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors

Fineline Cube Jan 22, 2026
Company Drug

Biogen Initiates TRANSCEND Study for Felzartamab in Late AMR Kidney Transplant Patients

Fineline Cube Mar 12, 2025

US-based Biogen Inc. (NASDAQ: BIIB) announced the initiation of the TRANSCEND study, a global Phase...

Company Deals

MindRank Ltd Receives FDA Clearance for MRANK-106 Clinical Study in Solid Tumors

Fineline Cube Mar 12, 2025

China-based artificial intelligence (AI)-enabled drug developer MindRank Ltd announced receiving clearance from the US Food...

Company Drug

AIM Vaccine Co. Ltd Announces Market Filing for Innovative Serum-Free Rabies Vaccine

Fineline Cube Mar 12, 2025

China-based AIM Vaccine Co., Ltd (HKG: 6660) announced plans to file for market approval for...

Company Deals

TowardPi Medical Secures RMB500 Million in Series E Round for Ophthalmic Equipment Expansion

Fineline Cube Mar 12, 2025

China-based TowardPi (Beijing) Medical Technology Ltd, a leading ophthalmology equipment R&D company, has reportedly secured...

Company Deals

WuXi XDC and AbTis Partner to Advance Antibody-Drug Conjugate Innovation

Fineline Cube Mar 12, 2025

WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA...

Company Drug

Ascletis Pharma’s ASC47 Shows Positive Results in Phase Ib Study for Weight Loss

Fineline Cube Mar 12, 2025

China-based Ascletis Pharma Inc. (HKG: 1672) announced positive topline results from a Phase Ib clinical...

Company Drug

AstraZeneca’s Imfinzi Approved by NMPA for Early-Stage NSCLC Treatment

Fineline Cube Mar 11, 2025

UK-based giant AstraZeneca (NASDAQ: AZN) received approval from China’s National Medical Products Administration (NMPA) for...

Company Medical Device

Huihe Healthcare’s K-Clip Wins Chinese Approval for Tricuspid Regurgitation Treatment

Fineline Cube Mar 11, 2025

Shanghai-based Huihe Healthcare, a developer of structural heart disease intervention medical devices, announced receiving marketing...

Company

Harbour BioMed Appoints Michael D. Patten as Chief Strategy Officer to Lead Global Growth

Fineline Cube Mar 11, 2025

China-based Harbour BioMed (HKG: 2142) announced the appointment of Michael D. Patten as Chief Strategy...

Company Deals

Genmab’s HexaBody-CD38 Clinical Development Halted After J&J Opt-Out

Fineline Cube Mar 11, 2025

Denmark-based Genmab A/S (NASDAQ: GMAB) announced that US giant Johnson & Johnson (J&J, NYSE: JNJ)...

Company Drug

Sichuan Kelun-Biotech’s Sacituzumab Tirumotecan Wins New NMPA Approval for NSCLC

Fineline Cube Mar 11, 2025

China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced receiving another indication approval from the...

Company

Illumina Responds to Chinese MOFCOM Notice Amid Sequencing Instrument Export Ban

Fineline Cube Mar 11, 2025

US major Illumina (NASDAQ: ILMN), which was included in a list of unreliable entities issued...

Company Drug

Huadong Medicine Seeks Regular Approval for Elahere in Ovarian Cancer Treatment

Fineline Cube Mar 11, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its application for converting conditional to...

Company Digital

Hansoh Pharmaceutical’s Ameile Wins New NMPA Approval for Advanced NSCLC Treatment

Fineline Cube Mar 11, 2025

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced receiving another indication approval from the...

Company Deals

IMEIK Technology Development Co.,Ltd Acquires Majority Stake in REGEN Biotech via Joint Venture

Fineline Cube Mar 11, 2025

China-based IMEIK Technology Development Co.,Ltd (SHE: 300896) announced the establishment of Imeik International Limited, a...

Company Drug

Lundbeck’s Amlenetug Receives Orphan Drug Designation in Japan for Multiple System Atrophy

Fineline Cube Mar 11, 2025

Denmark-based pharmaceutical company Lundbeck A/S (OTCMKTS: HLUBF) announced receiving Orphan Drug Designation (ODD) from Japan’s...

Company Deals

Shenzhen GeneMind Biosciences Partners with Precisiongenes for Molecular Diagnostic Innovation

Fineline Cube Mar 11, 2025

China-based gene sequencer specialist Shenzhen GeneMind Biosciences Co., Ltd. has formed a partnership with compatriot...

Company Deals

Juvensis Therapeutics Secures RMB100 Million for Heart Gene Therapy Development

Fineline Cube Mar 11, 2025

Shanghai-based Juvensis Therapeutics, a specialist in anti-aging therapies, reportedly raised upwards of RMB100 million (USD13.8...

Company Drug

Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for HRS-4029 in Acute Ischemic Stroke

Fineline Cube Mar 11, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced receiving clinical trial approval from the...

Company Drug

InnoCare Pharma Presents Positive Phase II Results of ICP-488 in Psoriasis at AAD Meeting

Fineline Cube Mar 10, 2025

China-based InnoCare Pharma (HKG: 9969, SHA: 688428) announced the oral presentation of results from the...

Posts pagination

1 … 144 145 146 … 612

Recent updates

  • Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal
  • Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors
  • Biokin’s Iza-bren ADC Receives NMPA Filing Acceptance for ESCC, World’s First EGFR×HER3 Bispecific
  • Kawin Technology Withdraws Hepatitis B Filing for Peginterferon Alfacon‑2 After NMPA Feedback
  • Eyebright Medical to Acquire Control of Delta Medical in $143 M Sports‑Medicine Deal
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals Drug

Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal

Company Drug

Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors

Company Drug

Biokin’s Iza-bren ADC Receives NMPA Filing Acceptance for ESCC, World’s First EGFR×HER3 Bispecific

Company Drug

Kawin Technology Withdraws Hepatitis B Filing for Peginterferon Alfacon‑2 After NMPA Feedback

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.